Epidemiology, natural evolution, pathogenesis, clinical spectrum, and management of Legg–Calvé–Perthes

• Published in: Journal of Children's Orthopaedics Vol. 17; no. 5; pp. 385 - 403
• Main Authors: Joseph, Benjamin, Shah, Hitesh, Perry, Daniel C
• Format: Book Review Journal Article
• Language: English
• Published: London, England SAGE Publications 01.10.2023; Sage Publications Ltd
• Subjects: Bone diseases; Epidemiology; Hip disorders; Necrosis; Orthopedics; Pediatrics; containment; Legg–Calvé–Perthes disease; social deprivation; weight-relief; declining incidence
• ISSN: 1863-2521; 1863-2548
• DOI: 10.1177/18632521231203009

Background: Legg–Calvé–Perthes disease is a self-limiting disorder that develops in children following interruption of the blood supply to the capital femoral epiphysis. This review outlines the current knowledge on the epidemiology, natural evolution, clinical spectrum, and management of the disease. Methods: The literature pertaining to these aspects of the disease were studied and summarized in this review. Results: Epidemiological studies suggest that environmental factors contribute to the causation of the disease. Incidence rates monitored over time indicate that the incidence of Legg–Calvé–Perthes disease is declining. The natural evolution followed on sequential plain radiographs enables division of the disease into Stages Ia, Ib, IIa, IIb, IIIa, IIIb, and IV. Reversible deformation of the capital occurs in Stages Ia–IIa simply on standing while irreversible deformation may occur in Stages IIb and IIIa. Treatment of Legg–Calvé–Perthes disease in Stages Ia–IIa aims to prevent the femoral head from getting deformed by containment and avoidance of weight-bearing. In Stages IIb and IIIa, treatment aims to remedy the effects of early irreversible deformation of the femoral head. In Stage IIIb and IV, treatment is directed to correcting the altered shape of the femoral head. The impression that these treatment methods are helpful is based on poor quality evidence. Conclusion: There is an urgent need to undertake Level I studies to establish the efficacy of currently treatment. Level of evidence: level V.